ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (NASDAQ:INHX) today announced its financial results for the first quarter ended March 31, 2011 and provided an update on recent clinical and corporate developments.
“Over the last few months we have achieved several important milestones and objectives”
“Over the last few months we have achieved several important milestones and objectives,” stated Russell H. Plumb, President and CEO of Inhibitex, Inc. “We believe the positive safety and antiviral results of our Phase 1b study of INX-189 support advancing it into Phase 2 studies, which we plan to initiate in the third quarter of 2011. Further, our recently-completed financing provides us with additional strategic flexibility and the capital resources to support the progress of INX-189 through these planned Phase 2 studies.”
